Titre : Tumeurs trophoblastiques

Tumeurs trophoblastiques : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Fields
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Tumeurs trophoblastiques : Questions médicales les plus fréquentes", "headline": "Tumeurs trophoblastiques : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Tumeurs trophoblastiques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-12", "dateModified": "2025-03-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Tumeurs trophoblastiques" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Complications tumorales de la grossesse", "url": "https://questionsmedicales.fr/mesh/D011252", "about": { "@type": "MedicalCondition", "name": "Complications tumorales de la grossesse", "code": { "@type": "MedicalCode", "code": "D011252", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Choriocarcinome", "alternateName": "Choriocarcinoma", "url": "https://questionsmedicales.fr/mesh/D002822", "about": { "@type": "MedicalCondition", "name": "Choriocarcinome", "code": { "@type": "MedicalCode", "code": "D002822", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720.949.208" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Choriocarcinome non gestationnel", "alternateName": "Choriocarcinoma, Non-gestational", "url": "https://questionsmedicales.fr/mesh/D031954", "about": { "@type": "MedicalCondition", "name": "Choriocarcinome non gestationnel", "code": { "@type": "MedicalCode", "code": "D031954", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720.949.208.438" } } }, { "@type": "MedicalWebPage", "name": "Tumeur trophoblastique du site d'implantation placentaire", "alternateName": "Trophoblastic Tumor, Placental Site", "url": "https://questionsmedicales.fr/mesh/D018245", "about": { "@type": "MedicalCondition", "name": "Tumeur trophoblastique du site d'implantation placentaire", "code": { "@type": "MedicalCode", "code": "D018245", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720.949.208.875" } } } ] }, { "@type": "MedicalWebPage", "name": "Maladie trophoblastique gestationnelle", "alternateName": "Gestational Trophoblastic Disease", "url": "https://questionsmedicales.fr/mesh/D031901", "about": { "@type": "MedicalCondition", "name": "Maladie trophoblastique gestationnelle", "code": { "@type": "MedicalCode", "code": "D031901", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720.949.416" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Môle hydatiforme", "alternateName": "Hydatidiform Mole", "url": "https://questionsmedicales.fr/mesh/D006828", "about": { "@type": "MedicalCondition", "name": "Môle hydatiforme", "code": { "@type": "MedicalCode", "code": "D006828", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720.949.416.875" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Môle invasive", "alternateName": "Hydatidiform Mole, Invasive", "url": "https://questionsmedicales.fr/mesh/D002820", "about": { "@type": "MedicalCondition", "name": "Môle invasive", "code": { "@type": "MedicalCode", "code": "D002820", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720.949.416.875.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Môle invasive", "alternateName": "Hydatidiform Mole, Invasive", "url": "https://questionsmedicales.fr/mesh/D002820", "about": { "@type": "MedicalCondition", "name": "Môle invasive", "code": { "@type": "MedicalCode", "code": "D002820", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720.949.416.875.500" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Tumeurs trophoblastiques", "alternateName": "Trophoblastic Neoplasms", "code": { "@type": "MedicalCode", "code": "D014328", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Maryam Shahi", "url": "https://questionsmedicales.fr/author/Maryam%20Shahi", "affiliation": { "@type": "Organization", "name": "Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA. Shahi.Maryam@mayo.edu." } }, { "@type": "Person", "name": "Wendy Allen-Rhoades", "url": "https://questionsmedicales.fr/author/Wendy%20Allen-Rhoades", "affiliation": { "@type": "Organization", "name": "Department of Pediatrics, Mayo Clinic, Rochester, MN, USA." } }, { "@type": "Person", "name": "Michael B Ishitani", "url": "https://questionsmedicales.fr/author/Michael%20B%20Ishitani", "affiliation": { "@type": "Organization", "name": "Department of Pediatric Surgery, Mayo Clinic, Rochester, MN, USA." } }, { "@type": "Person", "name": "Kevin M Elias", "url": "https://questionsmedicales.fr/author/Kevin%20M%20Elias", "affiliation": { "@type": "Organization", "name": "Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA; New England Trophoblastic Disease Center, Dana-Farber Cancer Institute, MA, USA." } }, { "@type": "Person", "name": "Ross S Berkowitz", "url": "https://questionsmedicales.fr/author/Ross%20S%20Berkowitz", "affiliation": { "@type": "Organization", "name": "Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA; New England Trophoblastic Disease Center, Dana-Farber Cancer Institute, MA, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Humphrey visual field made easy for residents.", "datePublished": "2024-09-27", "url": "https://questionsmedicales.fr/article/39331457", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4103/IJO.IJO_2519_23" } }, { "@type": "ScholarlyArticle", "name": "Detection of post-stroke visual field loss by quantification of the retrogeniculate visual pathway.", "datePublished": "2022-05-27", "url": "https://questionsmedicales.fr/article/35640329", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jns.2022.120297" } }, { "@type": "ScholarlyArticle", "name": "Foveal avascular zone vessel density is associated with visual field progression in early-stage glaucoma eyes with central visual field damage.", "datePublished": "2023-10-25", "url": "https://questionsmedicales.fr/article/37880406", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-45541-1" } }, { "@type": "ScholarlyArticle", "name": "Visual feedback in the lower visual field affects postural control during static standing.", "datePublished": "2022-07-08", "url": "https://questionsmedicales.fr/article/35843008", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.gaitpost.2022.07.004" } }, { "@type": "ScholarlyArticle", "name": "Five-Year Visual Field Outcomes of the HORIZON Trial.", "datePublished": "2023-02-21", "url": "https://questionsmedicales.fr/article/36813144", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajo.2023.02.008" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies urogénitales", "item": "https://questionsmedicales.fr/mesh/D000091642" }, { "@type": "ListItem", "position": 3, "name": "Maladies de l'appareil urogénital féminin et complications de la grossesse", "item": "https://questionsmedicales.fr/mesh/D005261" }, { "@type": "ListItem", "position": 4, "name": "Complications de la grossesse", "item": "https://questionsmedicales.fr/mesh/D011248" }, { "@type": "ListItem", "position": 5, "name": "Complications tumorales de la grossesse", "item": "https://questionsmedicales.fr/mesh/D011252" }, { "@type": "ListItem", "position": 6, "name": "Tumeurs trophoblastiques", "item": "https://questionsmedicales.fr/mesh/D014328" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Tumeurs trophoblastiques - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Tumeurs trophoblastiques", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Tumeurs trophoblastiques", "description": "Comment diagnostique-t-on une tumeur trophoblastique ?\nQuels marqueurs tumoraux sont utilisés ?\nLes échographies sont-elles utiles ?\nQuand faut-il suspecter une tumeur trophoblastique ?\nPeut-on utiliser l'IRM pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D014328?mesh_terms=Visual+Fields&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Tumeurs trophoblastiques", "description": "Quels sont les symptômes courants ?\nLes tumeurs trophoblastiques causent-elles des douleurs ?\nY a-t-il des symptômes systémiques ?\nLes nausées sont-elles fréquentes ?\nPeut-on avoir des symptômes sans grossesse récente ?", "url": "https://questionsmedicales.fr/mesh/D014328?mesh_terms=Visual+Fields&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Tumeurs trophoblastiques", "description": "Peut-on prévenir les tumeurs trophoblastiques ?\nLe suivi après une grossesse est-il important ?\nLes antécédents familiaux influencent-ils le risque ?\nLes femmes ayant eu des grossesses multiples sont-elles à risque ?\nY a-t-il des recommandations pour les femmes enceintes ?", "url": "https://questionsmedicales.fr/mesh/D014328?mesh_terms=Visual+Fields&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Tumeurs trophoblastiques", "description": "Quels traitements sont disponibles ?\nLa chimiothérapie est-elle efficace ?\nQuand la chirurgie est-elle nécessaire ?\nY a-t-il des effets secondaires des traitements ?\nLa radiothérapie est-elle utilisée ?", "url": "https://questionsmedicales.fr/mesh/D014328?mesh_terms=Visual+Fields&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Tumeurs trophoblastiques", "description": "Quelles complications peuvent survenir ?\nLes tumeurs trophoblastiques peuvent-elles être mortelles ?\nComment les métastases se manifestent-elles ?\nLes complications affectent-elles la fertilité ?\nY a-t-il des risques psychologiques associés ?", "url": "https://questionsmedicales.fr/mesh/D014328?mesh_terms=Visual+Fields&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Tumeurs trophoblastiques", "description": "Quels sont les principaux facteurs de risque ?\nL'âge joue-t-il un rôle ?\nLes antécédents médicaux influencent-ils le risque ?\nLes habitudes de vie affectent-elles le risque ?\nLes facteurs environnementaux sont-ils impliqués ?", "url": "https://questionsmedicales.fr/mesh/D014328?mesh_terms=Visual+Fields&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on une tumeur trophoblastique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sanguins, échographies et biopsies." } }, { "@type": "Question", "name": "Quels marqueurs tumoraux sont utilisés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux de l'hormone chorionique gonadotrope (hCG) sont souvent mesurés." } }, { "@type": "Question", "name": "Les échographies sont-elles utiles ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles permettent de visualiser les masses et d'évaluer leur taille." } }, { "@type": "Question", "name": "Quand faut-il suspecter une tumeur trophoblastique ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Après une grossesse, si des symptômes anormaux ou des niveaux d'hCG élevés persistent." } }, { "@type": "Question", "name": "Peut-on utiliser l'IRM pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'IRM peut être utilisée pour évaluer l'extension des tumeurs dans certains cas." } }, { "@type": "Question", "name": "Quels sont les symptômes courants ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des saignements vaginaux, douleurs abdominales et nausées." } }, { "@type": "Question", "name": "Les tumeurs trophoblastiques causent-elles des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs abdominales peuvent survenir en raison de la pression exercée." } }, { "@type": "Question", "name": "Y a-t-il des symptômes systémiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fatigue, la fièvre et la perte de poids peuvent apparaître." } }, { "@type": "Question", "name": "Les nausées sont-elles fréquentes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les nausées peuvent être fréquentes, surtout en cas de tumeur avancée." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes sans grossesse récente ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes peuvent apparaître même sans grossesse récente, nécessitant une évaluation." } }, { "@type": "Question", "name": "Peut-on prévenir les tumeurs trophoblastiques ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical est conseillé." } }, { "@type": "Question", "name": "Le suivi après une grossesse est-il important ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier peut aider à détecter précocement des anomalies." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de tumeurs trophoblastiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les femmes ayant eu des grossesses multiples sont-elles à risque ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les grossesses multiples peuvent augmenter le risque de tumeurs trophoblastiques." } }, { "@type": "Question", "name": "Y a-t-il des recommandations pour les femmes enceintes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi prénatal régulier est recommandé pour surveiller la santé maternelle et fœtale." } }, { "@type": "Question", "name": "Quels traitements sont disponibles ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chirurgie, la chimiothérapie et la surveillance." } }, { "@type": "Question", "name": "La chimiothérapie est-elle efficace ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la chimiothérapie est souvent efficace pour traiter les tumeurs trophoblastiques." } }, { "@type": "Question", "name": "Quand la chirurgie est-elle nécessaire ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La chirurgie est nécessaire si la tumeur est localisée et accessible." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires des traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme la fatigue, les nausées et la perte de cheveux peuvent survenir." } }, { "@type": "Question", "name": "La radiothérapie est-elle utilisée ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La radiothérapie est rarement utilisée, sauf dans des cas spécifiques de métastases." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des saignements, des infections et des métastases." } }, { "@type": "Question", "name": "Les tumeurs trophoblastiques peuvent-elles être mortelles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, si elles ne sont pas traitées, elles peuvent entraîner des complications graves." } }, { "@type": "Question", "name": "Comment les métastases se manifestent-elles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les métastases peuvent affecter les poumons, le foie et d'autres organes, causant divers symptômes." } }, { "@type": "Question", "name": "Les complications affectent-elles la fertilité ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines complications peuvent affecter la fertilité future des femmes." } }, { "@type": "Question", "name": "Y a-t-il des risques psychologiques associés ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diagnostic et le traitement peuvent entraîner des troubles psychologiques chez les patientes." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents de grossesse molaires, les grossesses multiples et l'âge maternel avancé." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les femmes de plus de 35 ans ont un risque accru de développer des tumeurs trophoblastiques." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de tumeurs trophoblastiques augmentent le risque de récidive." } }, { "@type": "Question", "name": "Les habitudes de vie affectent-elles le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines habitudes, comme le tabagisme, peuvent influencer le risque de complications." } }, { "@type": "Question", "name": "Les facteurs environnementaux sont-ils impliqués ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs environnementaux peuvent également jouer un rôle dans le développement de ces tumeurs." } } ] } ] }

Sources (10000 au total)

Humphrey visual field made easy for residents.

Visual field testing is an indispensable part of the assessment of glaucoma. Of paramount importance to both the practitioner and the perimetrist is the guidance on how to conduct the test to get the ... To simplify the basics of understanding single-field analysis of visual field tests by using the Humphrey perimeter.... The general principle and a brief overview of how the Humphrey visual field is conducted and the approach to interpreting the results of single field analysis in an easy-to-understand manner are prese... This educational video is an attempt to simplify the interpretation of Humphrey visual field single-field analysis with illustrations and video clips that would be useful to practicing ophthalmologist... https://youtu.be/x8iZLDR4XdY....

Foveal avascular zone vessel density is associated with visual field progression in early-stage glaucoma eyes with central visual field damage.

We investigated the relationship between foveal avascular zone (FAZ)-related parameters, assessed by optical coherence tomography angiography (OCT-A), and visual field (VF) progression in early-stage ...

Visual feedback in the lower visual field affects postural control during static standing.

The dorsal parietal visual system plays an important role in self-motion perception and spatial cognition. It also strongly responds to visual inputs from the lower visual field. Postural control is m... Do visual stimuli presented to the lower and upper visual fields affect postural control and sensory reweighting?... Twenty-nine healthy young adults participated in the study. Four conditions (full visual field, upper visual field, lower visual field, and no optic flow condition) were simulated in a VR environment ... Optic flow in the full and lower visual fields produced significantly smaller 95 % ellipse area and RMS of COP in the anterior-posterior direction compared to optic flow in the upper visual field. Furth... Visual feedback affects static postural control more when presented in the lower visual field compared to the upper visual field....

Five-Year Visual Field Outcomes of the HORIZON Trial.

To compare visual field (VF) progression between glaucoma patients receiving cataract surgery alone (CS) or with a Hydrus microstent (CS-HMS).... Post hoc analysis of VF data from the HORIZON multicenter randomized controlled trial.... A total of 556 patients with glaucoma and cataract were randomized 2:1 to either CS-HMS (369) or CS (187) and followed up for 5 years. VF was performed at 6 months and then every year after surgery. W... Data from 352 eyes in the CS-HMS arm and 165 in the CS arm were analyzed (2966 VFs). The mean RoP was -0.26 dB/y (95% credible interval -0.36, -0.16) for CS-HMS and -0.49 dB/y (95% credible interval -... CS-HMS has a significant effect on VF preservation in glaucoma patients compared with CS alone, reducing the proportion of fast progressors....

Effect of trabeculectomy on the rate of progression of visual field damage.

This study quantifies the effect of trabeculectomy on the rate of progression (RoP) of visual field (VF) damage utilising pre- and post-operative visual function as the outcome instead of surrogate ou... Clinical and VF data from 199 sequential patients who underwent trabeculectomy between 2015 and 2016 were extracted from the network of sites of Moorfields Eye Hospital NHS Foundation Trust. Of these,... We analysed 10 [9,12] VFs per subject (Median [Interquartile Range]). At surgery, the age was 67 [57, 72] years, mean deviation was -10.84 [-14.7, -5.6] dB and the IOP was 18 [15, 20] mmHg. One year a... Trabeculectomy leads to a significant reduction in the RoP of VF loss postoperatively....

A Consensus Statement on the Terminology for Automated Visual Field Abnormalities.

A multitude of terms have been used to describe automated visual field abnormalities. To date, there is no universally accepted system of definitions or guidelines. Variability among clinicians create... In phase one of the study, all neuro-ophthalmologists in Israel were asked to complete a survey in which they described the abnormalities in 10 selected automated visual field tests. In phase 2 of the... Twenty-six neuro-ophthalmologists participated in the initial survey. On average, there were 7.5 unique descriptions for each of the visual fields (SD 3.17), a description of only the location in 24.6... The study confirmed a great degree of variability in the use of terminology to describe automated visual field abnormalities. The creation of a consensus statement was associated with improved use of ...

Gaze tracker parameters have little association with visual field metrics of intrasession frontloaded SITA-Faster 24-2 visual field results.

To determine the usefulness of Humphrey Field Analyser (HFA) SITA-Faster 24-2 gaze tracker outputs on interpreting intra-visit visual field (VF) result pairs.... Analysis of 1380 right-left eye pairs and 1432 pairs of test 1-test 2 intrasession VF results of patients seen within a university-based glaucoma service was undertaken to understand gaze deviation di... There was no association of test order (right-left, test 1-test 2) with eye movements. There was a significant, but weak correlation between eye movements and age (r = 0.16). Correlations of eye movem... Eye movement parameters as currently reported by the HFA do not appear to be correlated with key sensitivity parameters when considering the repeatability of intrasession SITA-Faster 24-2 VF results. ...

Peripheral visual field loss and activities of daily living.

Peripheral visual field (VF) loss affects 13% of the population over 65. Its effect on activities of daily living and higher order visual processing is as important as it is inadequately understood. T... In this review, glaucoma and retrochiasmal cortical damage are utilized as examples of peripheral field loss which typically spare central vision and have patterns respecting the horizontal and vertic... Peripheral VF loss is an under-recognized cause of patient distress and disability. All peripheral field loss is not the same, differential patterns of loss affect parameters of activities of daily li...